Betagistin

General characteristics. Structure:

Active agent: betagistina dihydrochloride of 8 mg, 16 mg and 24 mg;
excipients: коповидон 5,2 mg, 10,4 mg, 15,6 mg; lactoses monohydrate (sugar milk) 41,6 mg, 83,2 mg, 124,8 mg; magnesium stearate of 1,0 mg, 2,0 mg, 3,0 mg; cellulose of microcrystallic 64,2 mg, 128,4 mg, 192,6 mg.

Description:
Tablets of color, almost white or white with a creamy shade, round, ploskotsilindrichesky with a facet (a dosage of 8 mg) or with a facet and risky (dosages of 16 mg and 24 mg). The insignificant mramornost is allowed.

Pharmacological properties:

Pharmacodynamics. Betagistin acts mainly on histamine with N |-and Nz-retseptory of an inner ear and vestibular nuclei of TsNS. By direct agonistic impact on N] - receptors of vessels of an inner ear. and also indirectly through impact on Nz-retseptory improves microcirculation and permeability of capillaries, normalizes endolymph pressure in a labyrinth and a snail. At the same time бетагистин increases a blood stream in a basilar artery.

Has the expressed central effect, being Nz-retseptorov inhibitor of kernels of a vestibular nerve. Improves conductivity in neurons of vestibular nuclei at the level of a brain trunk.

Clinical manifestation of the specified properties is decrease in frequency and intensity of dizzinesses, reduction of a sonitus, improvement of hearing in case of its decrease.

Pharmacokinetics. Communication with proteins of plasma — low is absorbed quickly. The maximum concentration in a blood plasma in 3 hours. An elimination half-life in 3–4 hours. It is almost completely removed by kidneys in the form of a metabolite (2-peridiluksusny acid) within 24 hours.

Indications to use:

Treatment and prevention of vestibular dizziness of various origin.
the syndromes including dizziness and a headache, a sonitus, the progressing decrease in hearing, nausea and vomiting.
disease or Menyer's syndrome.

Route of administration and doses:

Inside, during food.

Tablets of 8 mg: 1–2 tablets 3 times a day.
Tablets of 16 mg: 1/2-1 tablet 3 times a day.
Tablet of 24 mg: on 1 tablet 2 times a day.

Improvement is usually noted already at the beginning of therapy, the stable therapeutic effect occurs after two weeks of treatment and can increase within several months of treatment. Prolonged treatment. Duration of administration of drug is selected individuapno.

Side effects:

Gastrointestinal frustration, emergence of hypersensitivity reactions from integuments (rash. itch. small tortoiseshell), Quincke's edema.

Interaction with other medicines:

Cases of interaction or incompatibility with other medicines are unknown.
Influence on ability to driving and other mechanisms. Betagistin does not possess sedation and does not influence ability to drive the car or to be engaged in the types of activity demanding speed of psychomotor reactions.

Contraindications:

Hypersensitivity to any of drug components children up to 18 years (due to the lack of data).

With care
Peptic ulcer of digestive tract (including in the anamnesis), a pheochromocytoma. bronchial asthma. The specified patients should be observed regularly during treatment.

Pregnancy and period of a lactation

 There are not enough data for assessment of influence of drug during pregnancy and a lactation. In this regard reception at pregnancy is not recommended. For the period of treatment it is necessary to stop breastfeeding.

Overdose:

Symptoms: nausea, vomiting, spasms.
Treatment: gastric lavage, reception of absorbent carbon, symptomatic therapy.

Storage conditions:

List B. In the dry, protected from light place, at a temperature not above 25 °C. To store in the place unavailable to children. Period of validity 2 years. Not to use after expiry date.

Issue conditions:

According to the recipe

Packaging:

Tablets of 8 mg. 16 mg and 24 mg. On 10 or 30 tablets in a blister strip packaging. On 1, 2, 3 blister strip packagings on 10 tablets or on 1 blister strip packaging on 30 tablets in a pack cardboard together with the instruction.